top of page
gradientForSurfBreak.png

Item List

EIN News
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007

xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). Oblato is currently developing OKN-007 as a treatment for glioblastoma multiforme (GBM).

Recent Posts

Portfolio Company

Carlsmed.png

AI Used for Skin Cancer Checks at London Hospital
...

BBC

Portfolio Company

Carlsmed.png

CARTI Cancer Center Deploys DeepScribe's Ambient Operating System for Oncology ...

PR Newswire

Portfolio Company

Carlsmed.png

Ideem locks in $2.4M seed round for trust tech spinout driven by Toby Rush, star ...

Startland News

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page